Ovarian

AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer

(Merck) June 19, 2019 - AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA as a maintenance treatment after first-line chemotherapy in patients with BRCA-mutated (BRCAm) ovarian cancer. The approval in Japan was based on data from the randomized, double-blinded Phase 3 SOLO-1 trial which evaluated LYNPARZA as maintenance monotherapy compared with placebo in patients with BRCAm advanced ovarian cancer following first-line platinum-based chemotherapy.

read corporate press release

AZ Sees Triple Approval In Japan For Cancer and COPD Drugs

(Pharmaphorum [UK]) June 19, 2019 - AstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its cancer drug Lynparza, and two new combination therapies for patients with chronic obstructive pulmonary disease (COPD).

read article

Lynparza Approved In The EU For 1st-line Maintenance Treatment Of BRCA-Mutated Advanced Ovarian Cancer

(AstraZeneca) June 18, 2019 - AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer. The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of 1st-line platinum-based chemotherapy.

read corporate press release

AstraZeneca’s Lynparza Gets EU Nod As First-Line Ovarian Cancer Maintenance Treatment

(Reuters) June 18, 2019 - British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel’s consent in April. Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co, can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said.

read article

Out of Many Ovarian Precancerous Lesions, One Becomes Cancer

(Johns Hopkins Medicine) June 17, 2019 - Some deadly ovarian cancers arise from lesions genetically unrelated to each other.

read press release

American Cancer Society and Ovarian Cancer Research Alliance Launch New Ovarian Cancer Research Collaboration

(ACS) June 13, 2019 - Four multidisciplinary teams to be funded to study survivorship.

read press release

Clemson Researchers, Prisma Health Doctor Collaborate To Develop Screening Tool For Ovarian Cancer

(Clemson University/The Newsstand) June 4, 2019 - A team of researchers from Clemson University and Prisma Health–Upstate are working to create a screening process to catch ovarian cancer in the early or pre-cancerous stages.

read press release

NRG Oncology Trial Sets New Standard Regimen for Women with Uterine Carcinosarcomas

(NRG Oncology) June 3, 2019 - Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin (PC) to paclitaxel plus ifosfamide (PI) in women with stage I-IV, recurrent carcinosarcoma of the uterus or ovary, indicate that the PC combination treatment should be considered a standard of care for this patient population.

read press release

LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy

(Merck) June 3, 2019 - AstraZeneca and Merck, known as MSD outside the United States and Canada), today presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the treatment of platinum-sensitive relapsed patients with germline BRCA1/2-mutated (gBRCAm) advanced ovarian cancer, who have received two more prior lines of chemotherapy.

read corporate press release

Earlier Ovarian Cancer Diagnoses and Treatment Seen After ACA Implementation

(2019 ASCO) June 2, 2019 – An analysis of data from the National Cancer Database found that after implementation of the 2010 Affordable Care Act (ACA), ovarian cancer was diagnosed and treated at an earlier stage among women under age 65. More women also received treatment within 30 days of diagnosis, thereby increasing chances of survival. The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

read press release

Expanded Rubraca® (Rucaparib) Data From Clovis Oncology’s ARIEL3 And TRITON2 Trials In Ovarian And Prostate Cancers To Be Presented At 2019 ASCO Annual Meeting

(Clovis Oncology) June 1, 2019 - In exploratory analysis of ARIEL3 data, Rubraca significantly improved clinically meaningful endpoints including chemotherapy free interval and PFS on next therapy line for women with advanced ovarian cancer in maintenance treatment setting.

read corporate press release

IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival

(Associated Press) June 1, 2019 - IMV Inc. today announced that investigators shared new positive data for its DeCidE1 (DPX-Survivac with low dose Cyclophosphamide and Epacadostat) clinical trial at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting.

read article

ASCO: Phase 1 Clinical Trials Benefit Patients With Aggressive Ovarian Cancer

(UCCC/Colorado Cancer Blogs) May 31, 2019 - A University of Colorado Cancer Center study presented at the American Society of Clinical Oncology (ASCO) conference in Chicago indicates that there are therapeutic benefits for ovarian cancer patients that enroll in Phase 1 clinical trials.

read article

Clovis Oncology Presents Patient-Centered Outcomes Data From Phase 3 ARIEL3 Study For Rubraca® In Advanced Ovarian Cancer

(Clovis Oncology) May 20, 2019 - Quality-adjusted progression free survival (QA-PFS) and quality-adjusted time without cancer related symptoms or toxicity (Q-TWiST) demonstrate the benefit of Rubraca maintenance treatment over placebo from a patient perspective.

read corporate press release

‘This Terrible Disease’: Ovarian Cancer Is Deadly, But New Tests, Treatments Start To Emerge

(Washington Post) May 18, 2019 - Compared with other cancer success stories, the disease historically has had a shortage of good news. Until recently, it hasn’t benefited from new treatments for decades. For the past few years, as part of the University of Chicago Pritzker medical school obstetrics-gynecology rotation, med students at an optional lunchtime seminar hear from ovarian cancer survivors who share stories about the shock of diagnosis, painful treatments and constant worries about whether their cancer will come back.

read article (free registration required)

AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting

(AstraZeneca) May 16, 2019 - Presentations highlight LYNPARZA®’s benefit in PARP-mediated cancers and IMFINZI®’s three-year overall survival in unresectable, Stage III non-small cell lung cancer.

read corporate press release

ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer

(MarketWatch) May 15, 2019 - Combination demonstrates significant anti-tumor activity and favorable safety and tolerability in platinum-resistant disease. Findings support ongoing studies of doublet combination in platinum-agnostic disease and triplet in platinum-sensitive patients.

read article

Clovis Oncology Announces Presentations At 2019 ASCO Annual Meeting

(Clovis) May 16, 2019 - Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and the designs of other ongoing rucaparib trials.

read corporate press release

ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug

(The Street) May 15, 2019 - Shares of ImmunoGen plunge after the U.S. Food and Drug Administration requests additional trials to 'evaluate the safety and efficacy' of one of its cancer-fighting treatments. ImmunoGen said in statement that it had requested a meeting with FDA officials to discuss the results of its Phase 3 FORWARD I trial and a potential path to registration for mirvetuximab monotherapy - a treatment it has been developing for patients with certain forms of ovarian cancer.

read article

Circulating Tumor DNA Gives Treatment Options For The Most Common Ovarian Cancer

(University of Helsinki [Finland]) May 4, 2019 - According to a new research, circulating tumor DNA can be used detect treatment options for ovarian cancer patients who don’t benefit from chemotherapy.

read article
Next Page